Corbus Pharmaceuticals Holdings, Inc. (CRBP)
4.05
-0.08
(-1.94%)
USD |
NASDAQ |
Oct 23, 16:00
4.04
-0.01
(-0.25%)
After-Hours: 20:00
Corbus Pharmaceuticals Holdings Enterprise Value : -38.06M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -38.06M |
| October 22, 2026 | -36.56M |
| October 21, 2026 | -33.67M |
| October 20, 2026 | -31.15M |
| October 19, 2026 | -30.40M |
| October 16, 2026 | -29.28M |
| October 15, 2026 | -32.83M |
| October 14, 2026 | -31.34M |
| October 13, 2026 | -24.43M |
| October 12, 2026 | -15.28M |
| October 09, 2026 | -13.22M |
| October 08, 2026 | -15.28M |
| October 07, 2026 | -11.17M |
| October 06, 2026 | -5.756M |
| October 05, 2026 | -4.449M |
| October 02, 2026 | 0.7793M |
| October 01, 2026 | 4.700M |
| September 30, 2026 | 13.66M |
| September 29, 2026 | 10.12M |
| September 28, 2026 | 15.53M |
| September 25, 2026 | 19.64M |
| September 24, 2026 | 25.43M |
| September 23, 2026 | 30.84M |
| September 22, 2026 | 33.36M |
| September 21, 2026 | 29.16M |
| Date | Value |
|---|---|
| September 18, 2026 | 25.99M |
| September 17, 2026 | 21.88M |
| September 16, 2026 | 21.88M |
| September 15, 2026 | 15.53M |
| September 14, 2026 | 37.19M |
| September 11, 2026 | 37.94M |
| September 10, 2026 | 40.18M |
| September 09, 2026 | 51.75M |
| September 08, 2026 | 84.15M |
| September 04, 2026 | 93.20M |
| September 03, 2026 | 100.30M |
| September 02, 2026 | 100.67M |
| September 01, 2026 | 96.94M |
| August 31, 2026 | 90.03M |
| August 28, 2026 | 90.03M |
| August 27, 2026 | 94.14M |
| August 26, 2026 | 97.31M |
| August 25, 2026 | 97.50M |
| August 24, 2026 | 85.92M |
| August 21, 2026 | 80.13M |
| August 20, 2026 | 70.05M |
| August 19, 2026 | 72.85M |
| August 18, 2026 | 74.53M |
| August 17, 2026 | 82.19M |
| August 14, 2026 | 74.72M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -35.04M |
| Total Expenses (Quarterly) | 35.04M |
| EPS Diluted (Quarterly) | -1.805 |
| Earnings Yield | -152.5% |
| Normalized Earnings Yield | -152.51 |